Pentasa 2 gm/sachet (Microgranules)

2 gm sachet: ৳ 178.00 (1 x 60: ৳ 10,680.00)

Medicine Details

Category Details
Generic Mesalazine 5 aminosalicylic acid
Company Ferring pharmaceuticals ltd
Also available as
Pentasa 1 gm microgranules

Title

  • Pentasa

Categories

  • Gastrointestinal Medication
  • Treatment for Ulcerative Colitis and Crohn's Disease

Description

  • Pentasa is indicated for the treatment of mild to moderately active Ulcerative Colitis & Crohn’s Disease, maintenance of remission of Ulcerative Colitis, and maintenance of remission of Crohn’s disease.

DosageAndAdministration

  • Individual dosage for adults: up to 4 gm mesalazine once daily or divided into 2-4 doses, maintenance treatment: 2 gm mesalazine once daily. For children 6 years of age and older: active disease dosage starting with 30-50 mg/kg/day in divided doses, maintenance treatment dosage starting with 15-30 mg/kg/day in divided doses.

Indications

  • Treatment of mild to moderately active Ulcerative Colitis & Crohn’s Disease
  • Maintenance of remission of Ulcerative Colitis
  • Maintenance of remission of Crohn’s disease

Pharmacology

  • The mechanism of action of Mesalamine is unknown, but appears to be topical rather than systemic. Mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

Interaction

  • Concurrent use of other known nephrotoxic agents such as NSAIDs and Azathioprine may increase the risk of renal reactions.

Contraindications

  • Hypersensitivity to salicylates or to any other component of the formulation.

SideEffects

  • Commonly reported adverse events include headache, nausea, dizziness, asthenia, dyspepsia, vomiting, pruritus, etc.

PregnancyAndLactation

  • Should be given in pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised when it is administered to a nursing mother.

PrecautionsAndWarnings

  • Patients with pyloric stenosis may have prolonged gastric retention of Mesalamine tablets which could delay release of Mesalamine in the colon. Caution should be exercised when using Mesalamine in patients with known renal dysfunction or history of renal disease. Caution should be exercised when administering Mesalamine to patients with liver impairment.

UseInSpecialPopulations

  • Geriatrics: Caution should be taken to closely monitor blood cell counts during Mesalamine therapy. Elderly: Care should be taken when prescribing Pentasa therapy due to decreased renal function. Pediatric: Safety and effectiveness have not been established.

OverdoseEffects

  • There is no specific antidote for Mesalamine overdose. Treatment for suspected acute severe toxicity should be symptomatic and supportive. This is a pH dependent delayed-release product and this factor should be considered when treating a suspected overdose.

TherapeuticClass

  • Aminosalicylates

StorageConditions

  • Store below 30°C. Protect from light and moisture. Keep all medicines out of the reach of children.

Related Brands